Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
This sector is getting a lot of attention
Both drugs work the same way — turning off viral genes through an approach called RNA interference.
http://www.nytimes.com/2014/08/21/business/drug-used-for-ebola-related-virus-shows-promise.html?_r=0
"We are pleased to announce that Regen BioPharma has successfully achieved silencing of the IDO gene in human dendritic cells, which is a major step forward in development of our Investigational New Drug (IND) application to the FDA."
Hold on to your shares folks Month 6-18: Clinical Implementation:
Regen intends to launch clinical trials with world-leading institutions to obtain human safety data and "signal" of therapeutic efficacy. NEXT UP
"In biotechnology in general, and specifically in the area of regenerative medicine, the biggest value creation occurs for shareholders when a company files an IND and obtains human data that provides proof of safety and efficacy," said David R. Koos, Chairman and Chief Executive Officer of Bio-Matrix.
Bmsn Trading range since 8/11 to today has been .0028 to .0030 and have bounced off the 100 day on 60 min
that squeeze feels tight
It's The Game and Few Knows How It's Played....If I shorted a company I would bash it until I was forced to cover protecting my profits on the downside that's playing it smart...when I did cover I ride the baby on the upside ...even adding more to my position ...so both ways I make money...
All I see is a BIG BULLISH FLAG on the technical analysis flying on BMSN
Roy Bosa CEO of Vid3G, Inc. states that "With our management and technical team we are at the threshold of making a massive entry into the video technology market.
Soon VIDG will launch
Who Is Dan Clayton? and Why VIDG will win? - CTO-VID3G - Mr. Clayton excels in continuous innovation in internal application. He is a graduate of Harvard University with a degree in Computer Science & Engineering. Previously he was at DigitalNet where he was a Co-founder & CTO. The company was sold in 2004. Dan Clayton also works closely with the Institute of Computing Technology and China Academy of Sciences.
BAE Systems Unit to Buy DigitalNet
By Renae Merle
Washington Post Staff Writer
Monday, September 13, 2004; Page E01
BAE Systems North America announced a deal Saturday to acquire Herndon-based DigitalNet Holdings Inc. for $595 million in cash, pushing it further into the growing government information technology market.
The deal, which must be approved by shareholders, continues a consolidation of the market and would create an $1.2 billion information technology division ranked among the federal government's top 10 information technology providers.
added more
What I like about this job is knowing the downside and the upside I ask myself every morning when i look at my holdings including bmsn should Exit it or should add more Why? simple will my investment make me more money at this price point if my answer is yes I'll stay in even add more. If BMSN was to open at $1.00 would I sell or add more I would add more because it still would be dirt cheap Know What you own.
Understanding The Broader Application of Dcell vax
To Illustrate think of a switch what it does it turns off or turns on the energy flow to the source target.
think how switches are used in all sorts of application in your home on appliances in your car the workplace now understand a computer it a lot of switches that's on or off placed on micro chips each functions to do a specific task
What if you knew the first time a switch was made would you've bought it or invested in the company who discovered it, and it's functions?
Know what you own.
"Although Regen's focus with Dr. Min is the development of technology licensed from Benitec BioPharma to stimulate the immune system, in the form of dCellVax, the current publication illustrates the broad applicability of gene silencing technology, not only for immune stimulation, but also for targeted immune suppression," said Dr. Thomas Ichim, Chief Scientific Officer of Regen BioPharma. "In the case of dCellVax we are blocking immune suppressive genes to induce immune stimulation, whereas in this case, we silenced immune stimulatory genes to block only the part of the immune system that is responsible for rejection of heart transplants."
Organ transplants are the only available cure for end stage organ failure conditions such as heart, liver, and kidney failure. Although conventional immune suppressants are effective at blocking initial rejection of the transplanted organ, chronic usage of immune suppressants is associated with increased infections and incidence of cancer. This is because current drugs to treat transplant rejection globally suppress the immune system, making the body more susceptible to pathogens and cancer. In contrast, the approach described in the current publication selectively blocks the immune system from killing the transplanted heart, while allowing other components of the immune system to function normally.
"The current publication is an example of how work performed at Regen in the development of dCellVax has applications outside of its original intended field of use. Through our ongoing collaborative efforts we plan to not only accelerate the development of dCellVax in the area of breast cancer, but also to advance the field of gene silencing, which may have benefits in a wide variety of medical conditions," said David Koos, Chairman and CEO of Regen BioPharma Inc.
your estimates are conservative given you've not considered Wyy Working closely with three leading device and handset manufacturers to embed our Certificate-on-Device security offering into OEM equipment.
3rd and 4th qtr projections are commented to be even stronger at the pace wyy is moving the recent valuation at $6.50 may need to be moved up. Comments were made as to exceeding analyst expectation.
another mil coming through only 1 share filled
mm games 1 mil shares bought 1 filled and then 999,999
WidePoint Awarded G-Cloud 5 Framework Contract
WidePoint subsidiary Soft-ex selected as an approved provider for UK Government deals
ANY IDEAS OF HOW THIS WILL PLAY INTO REPORT TOMMORROW?
WidePoint has several major government and commercial contracts
VID3G Shareholder Update -- VID3G Anticipates New Launch Before the End of 2014
Marketwired
Vid3G, Inc. June 26, 2014 10:00 AM
Vid3G has completed the final beta version which will support the latest iOS version7.1.3 which is expected to be released before the end of the year. This is validation for Vid3G in the field of video technology. Finally the 700 million Chinese mobile users will have the opportunity to video and video stream on their smart-phones at the highest quality since Snapchat, Instagram and Twitter/Vine are not available in China. The Company intends to market their product initially through two of the largest social networks in China. Vid3G intends to have multiple launches, starting with China,
Hang on folks it's getting started....http://finance.yahoo.com/news/tencent-aims-undercut-alibaba-billion-160000688.html
it take guts to stay long but it pays
Krisandtilly Monday, 03/25/13 02:30:42 PM
Re: Intrepid2 post# 7810
Post # of 14993
are you long or day trading
the best advice I was ever given "the market will never do what you want it to do." Know what you want in any investments, cut your loses if you can't achieve it and move on.
possible for it to double bottom at .21 before take off(IMO)
adding more Liquidmetal reached a “significant milestone in our move to commercialize” the technology, said CEO Tom Steipp. The company settled a legal dispute over rights to the technology, and is preparing for the opening of a “manufacturing center of excellence” in October, said Steipp.
The company’s cash at the end of the quarter was $13.9 million, well up from $2.1 million at the end of last year.
Ladies and gentlemen the weather looks good for your flight we have clear sky no storm in the forecast.
Thomas Ichim, Chief Scientific Officer
investors your day is about to arrive
soon humans could be successfully treated and cured with this tech
up with 10,150 shares traded Price is manipulated MM? or someone else?(IMO)
WYY will be reporting its second quarter 2014 financial results on August 14, 2014, after the close of the market. Any guesses as to the reaction of the market? I've been accumulating.
any news? vidg up 53.33 %
If anyone believes in sltd You'll buy it at any price if the stock will make you a lot of money some trading style differs than others sltd is not a pump and dump stock(IMO) prove me wrong if you think so supply the details please.. this stock is trading like any other stock some buy and hold others swing it and yet others daytrade it take your pick whatever style you have the level of risk to handle.
AS for me I set my targets and wait if it don't hit I re-analize my charts and adjust accordingly to the market that's all anyone can do react to the market only fools predict it.(IMO)My thoughts sltd will be a great stock one day out of pennyland because it has the Tech and vision and a competent management team earnings at this stage of the game while others are still in the red is positive.in my fundamentals.
How does this tech stacks up against sltd... anyone? http://www.engadget.com/2014/08/08/stacking-solar-cells/?ncid=rss_truncated
Flight .0143 BMSN is on the runway Enjoy the ride ladies and Gentlemen
Skully My motto is buy companies that you can sleep at night any investment that'll keep me up I Dump it.BMSN so far I'm having good night rest.
It seems you have a problem with the science or with the company not sure which(JMO)to question the report that i can't help you My own DD suggest it's all true thus far if you could prove it's not then please provide the Details.
Thanks I consider myself as a savvy investor and don't allow my emotions to dictate my moves in an investment it's how i've made a lot of money so far.
I'm swing trading sltd all my indicators are firing I like to play it safe. I'll take a strong position again when the time is right.
I'm long on sltd and this is a great Company.
If .15 not supported we'll see sltd at .09(IMO)
Know what you own BMSN with the level of expertise note
A spokesperson for the Company provided further insight on RNAi, stating this is a process by which genes may be selectively blocked using a natural mechanism the body normally uses to protect against viruses. The Nobel Prize in Medicine was awarded to Fire and Mello in 2006 for making this discovery. Benitec has been granted international patents on RNAi which have been licensed to Regen for one specific gene, indolamine 2,3 deoxygenase (IDO), which is associated with cancer's ability to suppress the immune system.
Regen Chief Scientific Officer Dr. Thomas Ichim together with Professor Weiping Min at the University of Western Ontario have successfully treated breast cancer (1) and melanoma (2) in animals using this approach.
"With Regen's background in the field of tumor immunology, their licensed intellectual property from Benitec Biopharma, and clinical expertise, I look forward to assisting the Company in developing their protocols with the end goal being taking this safe and nontoxic cancer therapy to patients," said Dr. Suhy.
mm are Just test firing the engines before taking to flight